Thr290

Site Information
PIsPGPLtPMREKDV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3954994

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 )
Disease tissue studied:	breast cancer ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 , 10 , 11 , 14 ) , non-small cell lung cancer ( 5 , 11 , 14 ) , non-small cell lung cancer, surrounding tissue ( 12 , 13 , 15 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	A498 (renal) ( 7 ) , breast ( 1 ) , BT-20 (breast cell) ( 5 ) , BT-549 (breast cell) ( 5 ) , Calu 6 (pulmonary) ( 5 ) , H2009 (pulmonary) ( 5 ) , H2077 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , H322M (pulmonary) ( 5 ) , HCC2279 (pulmonary) ( 5 ) , HeLa (cervical) ( 8 , 9 , 16 ) , lung ( 10 , 11 , 12 , 13 , 14 , 15 ) , MDA-MB-231 (breast cell) ( 5 ) , MDA-MB-468 (breast cell) ( 5 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H157 (pulmonary) ( 5 ) , NCI-H1648 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 5 ) , NCI-H520 (squamous) ( 5 ) , PC9 (pulmonary) ( 5 ) , SH-SY5Y (neural crest) ( 4 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	LRRK2-IN-1 ( 4 ) , selumetinib ( 2 ) , vemurafenib ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
7	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
8	Moritz A (2010) CST Curation Set: 9056; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983 Curated Info
9	Moritz A (2010) CST Curation Set: 9057; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983 Curated Info
10	Rikova K (2009) CST Curation Set: 8550; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391 Curated Info
11	Rikova K (2009) CST Curation Set: 8538; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391 Curated Info
12	Rikova K (2009) CST Curation Set: 8540; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391 Curated Info
13	Rikova K (2009) CST Curation Set: 8512; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391 Curated Info
14	Rikova K (2009) CST Curation Set: 8514; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391 Curated Info
15	Rikova K (2009) CST Curation Set: 8508; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391 Curated Info
16	Moritz A (2008) CST Curation Set: 5068; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983 Curated Info